FDA expands the indication for Velcade for multiple myeloma patients.
Since 2003, multiple myeloma patients who have relapsed and who have had at least one prior therapy have been able to take Velcade (bortezomib, Millennium Pharmaceuticals, The Takeda Oncology Co., and Takeda Pharmaceutical Co.) to increase their survival. Now the Food & Drug Administration has granted the injection a new indication-for use among previously untreated patients with multiple myeloma. The International Myeloma Foundation applauded the FDA decision. Multiple myeloma is a cancer of the bone marrow and affects about 750,000 people worldwide.